Can higher doses of an H2‐receptor antagonist accelerate duodenal ulcer healing?

Publisher Website
Google Scholar
Abstract
SUMMARY: Drugs that inhibit gastric acid secretion heal duodenal ulcers at a rate that correlates with the ability of individual treatment regimens to decrease 24‐h intragastric acidity. As current therapeutic regimens of ranitidine decrease 24‐h intragastric acidity submaximally, higher dosages may expedite duodenal ulcer healing. To test this hypothesis a randomized, double‐blind clinical trial was conducted in 245 patients with duodenal ulcer to compare the effects of standard dose (300 mg nocte) and highdose (300 mg q.d.s.) ranitidine. Patients were assessed after 2 weeks of treatment and, if unhealed, after a further 2 weeks of therapy. The therapeutic gain in ulcer healing at the 2‐week endoscopy of the higher dose over the lower dose of ranitidine was 22% (68%vs 46%, P < 0.001). The cumulative ulcer healing rates at the 4‐week endoscopy were 88% and 92% for the standard and high‐dose ranitidine groups, respectively (N.S.). By 2 weeks, 61% of patients treated with standard ranitidine therapy and 79% of those receiving 300 mg ranitidine q.d.s. were pain‐free (P < 0.01). A further 2 weeks of therapy enabled 88% and 97% of patients (N.S.) to become pain‐free on these two regimens, respectively. The drug regimens were equally well tolerated. Thus higher‐dose ranitidine can significantly accelerate the healing of duodenal ulcer with improvement in pain relief.